Full text is available at the source.
Abstract
GLP1R agonists and GIPR/GLP1R dual agonists are being considered for repurposing to address heavy alcohol consumption and metabolic health.
- Metabolic dysfunction and heavy alcohol consumption are linked to increased liver disease progression.
- GLP1R agonists are currently used to treat diabetes and obesity.
- GIPR/GLP1R dual agonists are under investigation for metabolic dysfunction-associated liver conditions.
- There is ongoing research into the potential of these medications to reduce alcohol consumption.
- The dual-target approach may provide a solution for individuals facing both alcohol addiction and metabolic issues.
- Key unanswered questions remain regarding the effectiveness of metabolic circuit-based interventions in addiction treatment.
Simplified